OBJECTIVE: The objective of this study was to clarify the influence of p21 protein expression in ovarian cancer. p21 (WAF1 [wild-type p53 activated fragment 1]/CIP1) is a universal cyclin-dependent kinase inhibitor and can be induced as a downstream effector of the p53 tumor suppressor gene. METHODS: The expression of p21 was evaluated by immunohistochemical analysis with the monoclonal antibody WAF1 (Oncogene Science) on 106 formalin-fixed, paraffin-embedded tissue samples of epithelial ovarian cancer. RESULTS: p21 was expressed in 65 (61%) of all cases. p21 expression was associated with early stage in FIGO classification (FIGO I and II, P = 0.003) and no tumor residues after primary tumor resection (P = 0.018). Immunohistochemical staining results were judged as negative if no tumor nuclei were stained, as weak positive if 1-49% were stained, and as strong positive if over 50% of nuclei were stained. Clinical follow-up showed a better overall survival for cases with strong p21 expression (79 months) versus 40 months for weak expression and 30 months for no expression (P = 0.033). Previously determined p53 expression of this cohort was compared with p21 status. p53 overexpression was observed in 49 cases (48%) and showed no association with p21 expression. CONCLUSION: No correlation was found between p21 and p53 expression. p21 expression is a significant prognostic marker for improved survival in ovarian cancer and is associated with early FIGO stage and zero tumor residues after primary tumor resection. Copyright 2000 Academic Press.
OBJECTIVE: The objective of this study was to clarify the influence of p21 protein expression in ovarian cancer. p21 (WAF1 [wild-type p53 activated fragment 1]/CIP1) is a universal cyclin-dependent kinase inhibitor and can be induced as a downstream effector of the p53tumor suppressor gene. METHODS: The expression of p21 was evaluated by immunohistochemical analysis with the monoclonal antibody WAF1 (Oncogene Science) on 106 formalin-fixed, paraffin-embedded tissue samples of epithelial ovarian cancer. RESULTS:p21 was expressed in 65 (61%) of all cases. p21 expression was associated with early stage in FIGO classification (FIGO I and II, P = 0.003) and no tumor residues after primary tumor resection (P = 0.018). Immunohistochemical staining results were judged as negative if no tumor nuclei were stained, as weak positive if 1-49% were stained, and as strong positive if over 50% of nuclei were stained. Clinical follow-up showed a better overall survival for cases with strong p21 expression (79 months) versus 40 months for weak expression and 30 months for no expression (P = 0.033). Previously determined p53 expression of this cohort was compared with p21 status. p53 overexpression was observed in 49 cases (48%) and showed no association with p21 expression. CONCLUSION: No correlation was found between p21 and p53 expression. p21 expression is a significant prognostic marker for improved survival in ovarian cancer and is associated with early FIGO stage and zero tumor residues after primary tumor resection. Copyright 2000 Academic Press.
Authors: Annette Schmider-Ross; Olaf Pirsig; Elisabeth Gottschalk; Carsten Denkert; Werner Lichtenegger; Angela Reles Journal: J Cancer Res Clin Oncol Date: 2005-11-19 Impact factor: 4.553
Authors: Assaad Semaan; Aamer M Qazi; Shelly Seward; Sreedhar Chamala; Christopher S Bryant; Sanjeev Kumar; Robert Morris; Christopher P Steffes; David L Bouwman; Adnan R Munkarah; Donald W Weaver; Scott A Gruber; Ramesh B Batchu Journal: Pharm Res Date: 2011-08-05 Impact factor: 4.200
Authors: Huiyan Ma; Yaping Wang; Jane Sullivan-Halley; Linda Weiss; Polly A Marchbanks; Robert Spirtas; Giske Ursin; Ronald T Burkman; Michael S Simon; Kathleen E Malone; Brian L Strom; Jill A McDonald; Michael F Press; Leslie Bernstein Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701
Authors: Huiyan Ma; Xinxin Xu; Giske Ursin; Michael S Simon; Polly A Marchbanks; Kathleen E Malone; Yani Lu; Jill A McDonald; Suzanne G Folger; Linda K Weiss; Jane Sullivan-Halley; Dennis M Deapen; Michael F Press; Leslie Bernstein Journal: Cancer Med Date: 2015-04-27 Impact factor: 4.452
Authors: Pavla Brachova; Samuel R Mueting; Matthew J Carlson; Michael J Goodheart; Anna M Button; Sarah L Mott; Donghai Dai; Kristina W Thiel; Eric J Devor; Kimberly K Leslie Journal: Int J Oncol Date: 2014-11-11 Impact factor: 5.650
Authors: Ashley S Felix; Mark E Sherman; Stephen M Hewitt; Munira Z Gunja; Hannah P Yang; Renata L Cora; Vicky Boudreau; Kris Ylaya; Jolanta Lissowska; Louise A Brinton; Nicolas Wentzensen Journal: Front Oncol Date: 2015-02-09 Impact factor: 6.244
Authors: Huiyan Ma; Yani Lu; Kathleen E Malone; Polly A Marchbanks; Dennis M Deapen; Robert Spirtas; Ronald T Burkman; Brian L Strom; Jill A McDonald; Suzanne G Folger; Michael S Simon; Jane Sullivan-Halley; Michael F Press; Leslie Bernstein Journal: BMC Cancer Date: 2013-05-04 Impact factor: 4.430